Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer’s drug, Leqembi, by March 2024.

The company said the launch of Leqembi in the United States was progressing as planned and that 10,000 patients were expected to be on the drug by the end of March 2024.